

### Clinical Pharmacy Program Guidelines for Ingrezza

Program	Prior Authorization
Medication	Ingrezza® (valbenazine)
Market in Scope	Arizona, California, Colorado, Hawaii, Nevada, New Jersey, New York, New York EPP, Pennsylvania- CHIP, Rhode Island, South Carolina
Issue Date	10/2017
Pharmacy and Therapeutics Approval Date	11/2020
Effective Date	12/2020

**1. Background:**

Ingrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

**2. Coverage Criteria:**

<p><b>A. <u>Initial Authorization</u></b></p> <p>1. Diagnosis of moderate to severe tardive dyskinesia</p> <p style="text-align: center;"><b>-AND-</b></p> <p>2. <b><u>One</u></b> of the following:</p> <p style="padding-left: 40px;">a. Patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication</p> <p style="text-align: center;"><b>-OR-</b></p> <p style="padding-left: 40px;">b. Patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication</p> <p style="text-align: center;"><b>-AND-</b></p> <p>3. Prescribed by or in consultation with one of the following:</p> <ul style="list-style-type: none"> <li>• Neurologist</li> </ul>
--

- Psychiatrist

**Authorization will be issued for 12 months.**

**B. Reauthorization**

1. Documentation of positive clinical response to Ingrezza therapy

**Authorization will be issued for 12 months.**

**3. Additional Clinical Rules:**

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place

**4. References:**

1. Ingrezza [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.; April 2020.
2. Hauser RA, Factor SA, Marder SR, et al. Kinect 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. American Journal of Psychiatry. May 2017. 174:5.
3. Waln O, Jankovic J: An update on tardive dyskinesia: from phenomenology treatment. Tremor Other Hyperkinet Mov (NY) 2013; 3: tre-03-161-4138-1.

Program	Prior Authorization –Ingrezza (valbenazine)
<b>Change Control</b>	
Date	Change
10/2017	New program
10/2018	Annual review. Updated references.
8/2019	Annual review. Removed background note since applicable markets are outlined in the header.
11/2020	Annual review. Updated references. Added Additional Clinical Rules section.